Evidence map›Paper›PMID 39337633›Full record

ArticleInternational journal of molecular sciences2024

Sonodynamic Therapy for HER2+ Breast Cancer with Iodinated Heptamethine Cyanine-Trastuzumab Conjugate.

Dmytro Kobzev, Olga Semenova, Sarit Aviel-Ronen, Olesia Kulyk, Raanan Carmieli, Tajib Mirzabekov, Gary Gellerman, Leonid Patsenker

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dmytro KobzevDepartment of Chemical Sciences, Faculty of Natural Sciences, Ariel University, Ariel 40700, Israel.
Olga SemenovaDepartment of Chemical Sciences, Faculty of Natural Sciences, Ariel University, Ariel 40700, Israel.
Sarit Aviel-RonenAdelson School of Medicine, Ariel University, Ariel 40700, Israel.
Olesia KulykDepartment of Chemical Sciences, Faculty of Natural Sciences, Ariel University, Ariel 40700, Israel.
Raanan CarmieliDepartment of Chemical Research Support, Weizmann Institute of Science, Rehovot 76100, Israel.
Tajib MirzabekovBiomirex, Inc., 27 Strathmore Road, Natick, MA 01760, USA.
Gary GellermanDepartment of Chemical Sciences, Faculty of Natural Sciences, Ariel University, Ariel 40700, Israel.ORCID 0000-0002-1336-8707
Leonid PatsenkerDepartment of Chemical Sciences, Faculty of Natural Sciences, Ariel University, Ariel 40700, Israel.ORCID 0000-0002-5541-349X

Funding

Center for Absorption in Science of the Ministry of Immigrant Absorption of Israel KAMEAUnited States-Israel Binational Science Foundation 2021122
6 · The paper itself

Abstract

The first example of sonodynamic therapy (SDT) with a cyanine dye-antibody conjugate is reported. The aim of this study was to evaluate the sonodynamic efficacy of a trastuzumab-guided diiodinated heptamethine cyanine-based sensitizer,

Indexed as

Breast NeoplasmsCarbocyaninesErb-b2 Receptor Tyrosine KinasesTrastuzumabAnimalsCell Line, TumorFemaleHumansImmunoconjugatesMiceMice, NudePhotochemotherapyPhotosensitizing AgentsUltrasonic TherapyXenograft Model Antitumor AssaysCarbocyaninesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatesPhotosensitizing AgentsTrastuzumabantibody–sonosensitizer conjugateHER2-positive breast canceriodinated cyaninephotodynamic therapyreactive oxygen speciessonodynamic therapytargeted sonodynamic therapytrastuzumab

Identifiers

PMID39337633
PMCPMC11431973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.